Advertisement
News
Advertisement

Amarin treatment for high triglycerides shows progress in trials

Mon, 11/29/2010 - 10:36am
Mass High Tech: The Journal of New England Technology

Biopharmaceutical Amarin Corp. plc today is reporting positive, statistically significant top-line results from its first Phase 3 clinical trial of lead drug candidate AMR101, which is being investigated as a treatment for very high triglycerides.

Based in Dublin, Ireland, but with its R&D facilities in Mystic, Conn., Amarin (Nasdaq: AMRN) is a clinical-stage biopharmaceutical focused on cardiovascular disease.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading